Decipher Labs Ltd

DECIPHERPharmaceuticals
8.64+0.00 (+0.00%)
As on 29 Jan 2026, 10:34 amMarket Closed

Fundamental Score

...

Decipher Labs Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

1.16%
Poor

Return on Capital Employed

-4.67%
Poor

Operating Profit Margin (5Y)

1.23%
Poor

Dividend Yield

0.00%

Valuation Metrics

Price to Earnings

N/A

Market Capitalization

10.41 (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

101.50%
Poor

YoY Quarterly Sales Growth

-26.58%
Poor

Sales Growth (5Y)

-1.18%
Poor

EPS Growth (5Y)

-25.06%
Poor

Profit Growth (5Y)

-25.06%

Financial Health

Excellent

Debt to Equity

0.02x

Interest Coverage

N/A
Average

Free Cash Flow (5Y)

2.15 (Cr)

Ownership Structure

Poor

Promoter Holding

16.43%
Poor

FII Holding

0.00%
Poor

DII Holding

0.00%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
16.43%
Promoter Holding
10.41 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of DECIPHER across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Robust Profit Growth (101.50%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Conservative Debt Levels (D/E: 0.02)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

11 factors identified

Below-Average Return on Equity (1.16%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-4.67%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.

Margin Pressure Concerns (1.23%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.

Revenue Contraction (-26.58%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.

Limited Growth History (-1.18% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.

Weak Earnings Growth (-25.06% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.

Stagnant Profit Growth (-25.06% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.

Low Promoter Commitment (16.43%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

Very Low ROE

Observation: Poor capital utilization and shareholder returns.

Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Financial Statements

Comprehensive financial data for Decipher Labs Ltd

About DECIPHER

Business Overview

Decipher Labs Limited, together with its subsidiaries, manufactures, markets, sells, and trades in pharmaceutical drugs in India and internationally. It operates through Pharmaceutical and Consultancy segments. The company offers branded and finished formulations, bulk drugs, and chemicals. It also provides information technology (IT) consultancy services comprising technology integration and systems consulting, software development consulting, and management of IT projects. In addition, the company offers ERP implementation, mobile and cloud solutions, product development, and offshore services. It serves formulators, manufacturers, and research and development agencies. The company was formerly known as Combat Drugs Limited and changed its name to Decipher Labs Limited in January 2020. Decipher Labs Limited was incorporated in 1986 and is based in Hyderabad, India.

Company Details

Symbol:DECIPHER
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Ms. Sonam Jalan
Chief Financial Officer
Ms. Preeti Singh
Company Secretary & Compliance Officer
Amar Singh Dalavat
Marketing Head

DECIPHER Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)1.16%
Return on Capital Employed-4.67%
Operating Profit Margin (5Y)1.23%
Debt to Equity Ratio0.02
Interest Coverage RatioN/A

Growth & Valuation

Sales Growth (5Y)-1.18%
Profit Growth (5Y)-25.06%
EPS Growth (5Y)-25.06%
YoY Quarterly Profit Growth101.50%
YoY Quarterly Sales Growth-26.58%

Frequently Asked Questions

What is the current price of Decipher Labs Ltd (DECIPHER)?

As of 29 Jan 2026, 10:34 am IST, Decipher Labs Ltd (DECIPHER) is currently trading at ₹8.64. The stock has a market capitalization of ₹10.41 (Cr).

Is DECIPHER share price Overvalued or Undervalued?

DECIPHER is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.

What factors affect the Decipher Labs Ltd share price?

Key factors influencing DECIPHER's price include its quarterly earnings growth (Sales Growth: -26.58%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Decipher Labs Ltd a good stock for long-term investment?

Decipher Labs Ltd shows a 5-year Profit Growth of -25.06% and an ROE of 1.16%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing.

How does Decipher Labs Ltd compare with its industry peers?

Decipher Labs Ltd competes with major peers in the Pharmaceuticals. Investors should compare DECIPHER's P/E of 0.00x and ROE of 1.16% against the industry averages to determine its competitive standing.

What is the P/E ratio of DECIPHER and what does it mean?

DECIPHER has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.

How is DECIPHER performing according to Bull Run's analysis?

DECIPHER has a Bull Run fundamental score of 9/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does DECIPHER belong to?

DECIPHER operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Decipher Labs Ltd.

What is Return on Equity (ROE) and why is it important for DECIPHER?

DECIPHER has an ROE of 1.16%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Decipher Labs Ltd generates profits from shareholders' equity.

How is DECIPHER's debt-to-equity ratio and what does it indicate?

DECIPHER has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is DECIPHER's dividend yield and is it a good dividend stock?

DECIPHER offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has DECIPHER grown over the past 5 years?

DECIPHER has achieved 5-year growth rates of: Sales Growth -1.18%, Profit Growth -25.06%, and EPS Growth -25.06%.

What is the promoter holding in DECIPHER and why does it matter?

Promoters hold 16.43% of DECIPHER shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is DECIPHER's market capitalization category?

DECIPHER has a market capitalization of ₹10 crores, placing it in the Small-cap category.

How volatile is DECIPHER stock?

DECIPHER has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for DECIPHER?

DECIPHER has a 52-week high of ₹N/A and low of ₹N/A.

What is DECIPHER's operating profit margin trend?

DECIPHER has a 5-year average Operating Profit Margin (OPM) of 1.23%, indicating the company's operational efficiency.

How is DECIPHER's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of -26.58% and YoY Profit Growth of 101.50%.

What is the institutional holding pattern in DECIPHER?

DECIPHER has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.